The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

The present invention relates to solid oral pharmaceutical compositions for chronotropic administration of sartans, consisting of a monolithic matrix core comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac and an outer coating of said core consisting of a layer comprising ethyl cellulose, a gastroresistant layer, or a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.

The invention relates to compound of formula (I)

##STR00001##

wherein R.sup.1 to R.sup.3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

The present invention is directed to a soft chewable composition comprising or containing a therapeutically effective amount of a veterinary active agent, preferably a JAK inhibitor; an animal based palatant, a non-animal based palatant, a flavor modifier, and at least one veterinary acceptable excipient that is selected from at least one each of a disintegrant, binder, lubricant, humectant, and glidant; and wherein the soft chewable tablet is compressed with a rotary tablet press; and methods for treating or preventing cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with allergic dermatitis, allergies, and chronic respiratory disease in an animal.

Disclosed is the 3D printing of pharmaceutical formulations, such as tablets, wherein a binder liquid is deposited dropwise on a layer of powder, with these steps being repeated, in one or more patterns, in order to generate a solid drug product. In accordance with the invention, the powder comprises lactose particles having a particle size distribution characterized by a D10 of at least 6 μm.

This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.

The present application relates to the technical field of medicine processing, in particular to a toner, a lysozyme buccal tablet and a preparation method of the lysozyme buccal tablet. The toner is obtained by formulating a pigment suspension through adding purified water into the pigment, then atomizing and spraying the pigment suspension onto dextrin, mixing thoroughly, drying and pulverizing. The application further discloses a lysozyme buccal tablet and a preparation method thereof.

Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.